A Study of Inhibitory Interneurons (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Focal Seizures
The purpose of this research is to test the safety of an investigational NRTX-1001 cell therapy in participants with drug resistant bilateral mesial temporal lobe epilepsy (MTLE). Another purpose is to see if NRTX-1001 can reduce the number of seizures you have.
Why this Research Matters
This study is designed to primarily assess the safety and tolerability of NRTX-1001 in participants with drug resistant bilateral mesial temporal lobe epilepsy (MTLE). A secondary objective is to observe the impact of NRTX-1001 on seizure frequency. Neurona Therapeutics is studying an investigational cell therapy called NRTX-1001 as a possible treatment for drug resistant bilateral MTLE. NRTX-1001 is called investigational as it has not been approved by the U.S. Food and Drug Administration (FDA).
Who can Participate
Diagnosis of drug-resistance bilateral mesial temporal lobe epilepsy with mesial temporal sclerosis
Study ID
Protocol Number: 24-1207
More information available at ClinicalTrials.gov: NCT06422923
Meet the Team
Principal Investigator